Three stocks for the long term that the market has missed

Professional investor Adam Khanbhai highlights three stocks where he believes the market is missing the broader long-term picture.

In periods of heightened uncertainty, the value of a rigorous and disciplined investment process cannot be overstated. Decisions based on either the fear of missing out or on a “wait and see” approach are unlikely to lead to success. We focus on UK-listed small-cap stocks, seeking out those likely to benefit from structural growth and boasting high-quality earnings and cash generation. 

We aim to buy companies at a discount to their “real world” value to a private equity or corporate buyer and to invest for the long term. This framework has helped us cut through the constant barrage of news about Covid-19 to identify opportunities where we believe the market is missing the broader long-term picture (even if there is short-term disruption).

Clinigen will close the value gap

A classic example of a major gulf between a firm’s fundamentals and its share price is Clinigen Group (Aim: CLIN). Clinigen provides pharmaceutical products to healthcare providers in more than 120 countries. As most of these medicines are for critical and chronic conditions, there has been limited disruption to date. Still, the shares plunged from 900p to 360p as markets slumped, prompting us to top up our holding. 

Although the shares have since recovered somewhat, we believe the company is a unique asset that remains materially undervalued. Furthermore, recently acquired drug Proleukin is being used in numerous clinical trials alongside immunology cancer treatments. Its potential has yet to be factored in to both current forecasts and the share price.

Medica Group (LSE: MGP) has been affected by Covid-19, but is well positioned to emerge stronger on the other side. The company provides teleradiology services that enable medical images to be interpreted remotely by radiologists. A structural shortage of radiologists and increasing demand for imaging is driving strong growth: revenues increased by 19% last year. 

Although scan volumes are currently severely affected as the NHS focuses on Covid-19, the company has a variable cost base and a net cash position that should enable it to ride out a prolonged period of disruption. Medica is currently deepening its relationship with the NHS by providing the health service with its remote-working technology and this will stand it in good stead once normal activity resumes. Dr Stuart Quin, CEO since September, has an excellent record of delivering value for shareholders.

A resilient share registrar

The share registrar and financial services provider Equiniti Group (LSE: EQN) is a core holding, with a key attraction being the resilience of the underlying business model. Around 80% of sales stem from long-term recurring contracts. While discretionary revenue streams such as those relating to merger and acquisition activity have been affected by the crisis, more rights issues and share placings will offset some of this. 

We expect the business to remain profitable, cash generative and well capitalised this year. Longer term, there is opportunity in the US now that Equiniti’s strategic acquisition there has been fully integrated. The shares have fallen by around 25% since February to 150p –  an attractive entry point into a high-quality company.

Recommended

Should you buy Vodafone shares, or steer clear?
Share tips

Should you buy Vodafone shares, or steer clear?

Vodafone grew revenue by 4% and profit by 11% last year, and offers investors a 6.4% dividend yield. So should you buy Vodafone shares? Rupert Hargrea…
17 May 2022
Melrose Industries: a British manufacturer that is well-placed for recovery
Share tips

Melrose Industries: a British manufacturer that is well-placed for recovery

Melrose, the aerospace and automotive manufacturer, has been hit by the pandemic, but the shares are unduly cheap says David J Stevenson.
17 May 2022
Avoid easyJet shares – there are better airlines to invest in
Share tips

Avoid easyJet shares – there are better airlines to invest in

EasyJet used to be one of Europe’s most impressive airlines. But now it is facing challenges on all fronts and losing out to the competition. Rupert …
16 May 2022
A family-run investment trust to buy and lock away
Investment trusts

A family-run investment trust to buy and lock away

Menhaden Resource Efficiency made a slow start, but progress is encouraging. Buy before the discount closes, says Max King.
16 May 2022

Most Popular

Get set for another debt binge as real interest rates fall
UK Economy

Get set for another debt binge as real interest rates fall

Despite the fuss about rising interest rates, they’re falling in real terms. That will blow up a wild bubble, says Matthew Lynn.
15 May 2022
Is the oil market heading for a supply glut?
Oil

Is the oil market heading for a supply glut?

Many people assume that the high oil price is here to stay – and could well go higher. But we’ve been here before, says Max King. History suggests tha…
16 May 2022
High inflation will fade – here’s why
Inflation

High inflation will fade – here’s why

Many people expect high inflation to persist for a long time. But that might not be true, says Max King. Inflation may fall faster than expected – and…
13 May 2022